{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:04:51Z","timestamp":1783991091356,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-026-05130-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:32:35Z","timestamp":1779287555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus statement on the management of metastatic colorectal cancer beyond the second-line therapy in Saudi Arabia"],"prefix":"10.1007","volume":"41","author":[{"given":"Shouki","family":"Bazarbashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsharm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Ibnshamsah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Tashkandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanan","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Al-Hajeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mahrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alghmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aljubran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Alkhayyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereef","family":"Elsamany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"5130_CR1","unstructured":"World Health Organization (2026) Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer"},{"key":"5130_CR2","volume-title":"Cancer today","author":"International Agency for Research on Cancer","year":"2020","unstructured":"International Agency for Research on Cancer (2020) Cancer today. Global Cancer Observatory. https:\/\/gco.iarc.fr\/today\/home"},{"issue":"8","key":"5130_CR3","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-043","volume":"19","author":"A Jemal","year":"2010","unstructured":"Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893\u20131907. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-043","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"5130_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Sauer AG, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70(3):145\u2013164. https:\/\/doi.org\/10.3322\/caac.21601","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5130_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5144\/0256-4947.2015.196","volume":"35","author":"N Alsanea","year":"2015","unstructured":"Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S (2015) Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med 35(3):196\u2013202. https:\/\/doi.org\/10.5144\/0256-4947.2015.196","journal-title":"Ann Saudi Med"},{"key":"5130_CR6","unstructured":"World Health Organization (2023) Colorectal cancer. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/colorectal-cancer"},{"issue":"2","key":"5130_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/pg.2018.81072","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89\u2013103. https:\/\/doi.org\/10.5114\/pg.2018.81072","journal-title":"Prz Gastroenterol"},{"key":"5130_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2147\/IJGM.S277272","volume":"13","author":"A Almatroudi","year":"2020","unstructured":"Almatroudi A (2020) The incidence rate of colorectal cancer in Saudi Arabia: an observational descriptive epidemiological analysis. Int J Gen Med 13:977\u2013990","journal-title":"Int J Gen Med"},{"key":"5130_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.730689","volume":"11","author":"M Alyabsi","year":"2021","unstructured":"Alyabsi M, Algarni M, Alshammari K (2021) Trends in colorectal cancer incidence rates in Saudi Arabia (2001\u20132016) using Saudi National Registry: early- versus late-onset disease. Front Oncol 11:730689","journal-title":"Front Oncol"},{"key":"5130_CR10","doi-asserted-by":"crossref","unstructured":"Alfahed A (2023) Molecular pathology of colorectal cancer: the Saudi situation in perspective. Saudi Med J 44","DOI":"10.15537\/smj.2023.44.9.20230257"},{"key":"5130_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12885-024-12270-1","volume":"24","author":"N Alsadhan","year":"2024","unstructured":"Alsadhan N, Alhurishi SA, Pujades-Rodriguez M, Shuweihdi F, Brennan C, West RM (2024) Demographic and clinical characteristics associated with advanced stage colorectal cancer: a registry-based cohort study in Saudi Arabia. BMC Cancer 24:533","journal-title":"BMC Cancer"},{"issue":"3","key":"5130_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/gidisord7030056","volume":"7","author":"L Alrubaiy","year":"2025","unstructured":"Alrubaiy L, El-Sayed A, Kapila D, Akintimehin A, Wijeyendram P (2025) Colorectal cancer screening in the Middle East and North Africa: current practices, challenges, and insights from the British Society of Gastroenterology (BSG) International Section. Gastrointest Disord 7(3):56","journal-title":"Gastrointest Disord"},{"key":"5130_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s10900-025-01475-5","volume":"50","author":"L Mohamedali","year":"2025","unstructured":"Mohamedali L, Al-Kubaisi M, Alhaj Ahmad S, Haroon S, Alshalkhaty A, Hussein DM et al (2025) Assessing colorectal cancer awareness and preventive lifestyle practices in the United Arab Emirates: a comparative study of risk groups. J Community Health 50:1018\u20131028","journal-title":"J Community Health"},{"key":"5130_CR14","doi-asserted-by":"publisher","first-page":"1507563","DOI":"10.3389\/fnut.2025.1507563","volume":"12","author":"AA Alkhaldy","year":"2025","unstructured":"Alkhaldy AA (2025) Knowledge, attitudes, and practices toward colorectal cancer lifestyle risk factors among adults in Saudi Arabia. Front Nutr 12:1507563","journal-title":"Front Nutr"},{"key":"5130_CR15","unstructured":"Al-Ahmadi K, Al-Zahrani A, Al-Ahmadi S (2013) Spatial accessibility to cancer care facilities in Saudi Arabia. In: Proceedings of the Esri Health GIS Conference; October 14\u201316, Cambridge, MA"},{"key":"5130_CR16","doi-asserted-by":"crossref","unstructured":"Elwali NE, Jarrah O, Alzahrani SG, Alharbi MB, Alhejaily AG, Alsharm AA et al (2023) Colorectal cancer in Saudi Arabia: the way forward. Asian Pac J Cancer Prev 24(1)","DOI":"10.31557\/APJCP.2023.24.1.13"},{"issue":"5","key":"5130_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.6004\/jnccn.2017.0077","volume":"15","author":"WA Messersmith","year":"2017","unstructured":"Messersmith WA (2017) Systemic management of colorectal cancer. J Natl Compr Canc Netw 15(5):699\u2013702","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"5130_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609\u20131618","journal-title":"N Engl J Med"},{"issue":"8","key":"5130_CR19","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"3","key":"5130_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100156","volume":"6","author":"G Patelli","year":"2021","unstructured":"Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patan\u00e8 DA et al (2021) Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open 6(3):100156","journal-title":"ESMO Open"},{"issue":"5","key":"5130_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C et al (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23(5):659\u2013670","journal-title":"Lancet Oncol"},{"issue":"10476","key":"5130_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E et al (2025) Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet 405(10476):383\u2013395","journal-title":"Lancet"},{"issue":"4","key":"5130_CR23","first-page":"372","volume":"16","author":"M Tampellini","year":"2017","unstructured":"Tampellini M, Di Maio M, Baratelli C, Anania L, Brizzi MP, Sonetto C et al (2017) Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit. Clin Colorectal Cancer 16(4):372\u2013376","journal-title":"Clin Colorectal Cancer"},{"issue":"10","key":"5130_CR24","first-page":"896","volume":"26","author":"Food and Drug Administration","year":"2012","unstructured":"Food and Drug Administration (2012) FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 26(10):896","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"5130_CR25","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/1078-0432.CCR-17-0720","volume":"23","author":"L Marcus","year":"2017","unstructured":"Marcus L, Lemery SJ, Khasar S, Wearne E, Helms WS, Yuan W et al (2017) FDA approval summary: TAS-102. Clin Cancer Res 23(12):2924\u20132927. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0720","journal-title":"Clin Cancer Res"},{"key":"5130_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00461","volume":"10","author":"S Bazarbashi","year":"2024","unstructured":"Bazarbashi S, Alkhatib R, Aseafan M, Tuleimat Y, Abdel-Aziz N, Mahrous M et al (2024) Efficacy of chemotherapy rechallenge versus regorafenib or trifluridine\/tipiracil in third-line setting of metastatic colorectal cancer: a multicenter retrospective comparative study. JCO Glob Oncol 10:e2300461. https:\/\/doi.org\/10.1200\/GO.23.00461","journal-title":"JCO Glob Oncol"},{"key":"5130_CR27","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/j.clcc.2018.08.00","volume":"17","author":"SK Cho","year":"2018","unstructured":"Cho SK, Hay JW, Barzi A (2018) Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States. Clin Colorectal Cancer 17:e751\u2013e761. https:\/\/doi.org\/10.1016\/j.clcc.2018.08.00","journal-title":"Clin Colorectal Cancer"},{"issue":"28_suppl","key":"5130_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2020.39.28_suppl.74","volume":"39","author":"JM Unger","year":"2021","unstructured":"Unger JM, Fleury M (2021) Nationally representative estimates of the participation of cancer patients in clinical research studies according to the Commission on Cancer. J Clin Oncol 39(28_suppl):74. https:\/\/doi.org\/10.1200\/JCO.2020.39.28_suppl.74","journal-title":"J Clin Oncol"},{"key":"5130_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.2217\/fon-2022-1253","volume":"19","author":"B Moss","year":"2023","unstructured":"Moss B, Goodall EA, Maravic Z, Marti F, Moss M, Rowley S et al (2023) Real-world evidence research in metastatic colorectal cancer: raising awareness of the need for patient contributions. Future Oncol 19:2329\u20132337. https:\/\/doi.org\/10.2217\/fon-2022-1253","journal-title":"Future Oncol"},{"issue":"4","key":"5130_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67(4):401\u2013409. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"5130_CR31","doi-asserted-by":"publisher","first-page":"i\u2013iv, 1\u201388","DOI":"10.3310\/hta2030","volume":"2","author":"MK Murphy","year":"1998","unstructured":"Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J et al (1998) Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2(3):i\u2013iv, 1\u201388. https:\/\/doi.org\/10.3310\/hta2030","journal-title":"Health Technol Assess"},{"issue":"7","key":"5130_CR32","doi-asserted-by":"publisher","first-page":"A644","DOI":"10.1016\/j.jval.2014.08.233","volume":"17","author":"F Heiman","year":"2014","unstructured":"Heiman F, Ripellino C, Visentin E (2014) Real world data in oncology: third- and fourth-line treatments administered in metastatic colon-rectal cancer (MCRC). Value Health 17(7):A644. https:\/\/doi.org\/10.1016\/j.jval.2014.08.233","journal-title":"Value Health"},{"issue":"4","key":"5130_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.21873\/anticanres.10845","volume":"36","author":"S Arita","year":"2016","unstructured":"Arita S, Shirakawa T, Matsushita Y, Shimokawa HK, Hirano G, Makiyama A et al (2016) Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Res 36(4):1959\u20131966. https:\/\/doi.org\/10.21873\/anticanres.10845","journal-title":"Anticancer Res"},{"issue":"15","key":"5130_CR34","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne CH, L\u00e1ng I, Folprecht G, Nowacki MP, Cascinu S et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011\u20132019. https:\/\/doi.org\/10.1200\/JCO.2010.33.5091","journal-title":"J Clin Oncol"},{"issue":"1","key":"5130_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS. SSO and TOS. Ann Oncol 29(1):44\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdx738","journal-title":"SSO and TOS. Ann Oncol"},{"key":"5130_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87\u201398. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.007","journal-title":"Eur J Cancer"},{"key":"5130_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.2017.35.15_suppl.741","volume":"35","author":"T Nagaoka","year":"2017","unstructured":"Nagaoka T et al (2017) Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines. J Clin Oncol 35:741. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.741","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"5130_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO.2018.36.4_suppl.748","volume":"36","author":"H Schulz","year":"2018","unstructured":"Schulz H, Janssen J, Strauss UP, Langen M, Dworschak KU, Fiala-Buskies S et al (2018) Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: final results of the prospective multicentre non-interventional RECORA study. J Clin Oncol 36(4_suppl):748. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.748","journal-title":"J Clin Oncol"},{"issue":"6","key":"5130_CR39","doi-asserted-by":"publisher","first-page":"vi167","DOI":"10.1093\/annonc\/mdw370.54","volume":"27","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero R, Van Cutsem E, Ciardiello F, Ychou M, Seitz JF, Hofheinz RD et al (2016) Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Ann Oncol 27(6):vi167","journal-title":"Ann Oncol"},{"issue":"9863","key":"5130_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 381(9863):303\u2013312","journal-title":"The Lancet"},{"issue":"6","key":"5130_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629","journal-title":"Lancet Oncol"},{"key":"5130_CR42","doi-asserted-by":"publisher","first-page":"117955491882544","DOI":"10.1177\/1179554918825447","volume":"13","author":"A Aljubran","year":"2019","unstructured":"Aljubran A, Elshenawy MA, Kandil M, Zahir MN, Shaheen A, Gad A et al (2019) Efficacy of regorafenib in metastatic colorectal cancer: a multi-institutional retrospective study. Clin Med Insights Oncol 13:1179554918825447. https:\/\/doi.org\/10.1177\/1179554918825447","journal-title":"Clin Med Insights Oncol"},{"key":"5130_CR43","doi-asserted-by":"publisher","first-page":"3796783","DOI":"10.1155\/2022\/3796783","volume":"2022","author":"M Alghamdi","year":"2022","unstructured":"Alghamdi M, Bazarbashi S, Mahrous M, Alshaer O, Mostafa Gad A, Aseafan M et al (2022) Outcomes of patients with metastatic colorectal cancer treated with trifluridine\/tipiracil beyond the second line: a multicenter retrospective study from Saudi Arabia. J Oncol 2022:3796783. https:\/\/doi.org\/10.1155\/2022\/3796783","journal-title":"J Oncol"},{"issue":"1","key":"5130_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10\u201332","journal-title":"Ann Oncol"},{"key":"5130_CR45","doi-asserted-by":"publisher","first-page":"175883592095686","DOI":"10.1177\/1758835920956862","volume":"12","author":"F Loupakis","year":"2020","unstructured":"Loupakis F, Antonuzzo L, Bachet JB et al (2020) Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol 12:1758835920956862","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"5130_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdy526","volume":"30","author":"K Shitara","year":"2019","unstructured":"Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y et al (2019) REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 30(2):259\u2013265. https:\/\/doi.org\/10.1093\/annonc\/mdy526","journal-title":"Ann Oncol"},{"issue":"4","key":"5130_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.clcc.2017.03.017","volume":"16","author":"H Vanwynsberghe","year":"2017","unstructured":"Vanwynsberghe H, Verbeke X, Coolen J, Van Cutsem E (2017) Predictive value of early tumor shrinkage and density reduction of lung metastases in patients with metastatic colorectal cancer treated with regorafenib. Clin Colorectal Cancer 16(4):377\u2013380. https:\/\/doi.org\/10.1016\/j.clcc.2017.03.017","journal-title":"Clin Colorectal Cancer"},{"key":"5130_CR48","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"M Suenaga","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 9:3099\u20133108. https:\/\/doi.org\/10.2147\/DDDT.S85567","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"5130_CR49","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/annonc\/mdh305","volume":"15","author":"F Maindrault-Goebel","year":"2004","unstructured":"Maindrault-Goebel F, Tournigand C, Andr\u00e9 T, Carola E, Mabro M, Artru P et al (2004) Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15(8):1210\u20131214. https:\/\/doi.org\/10.1093\/annonc\/mdh305","journal-title":"Ann Oncol"},{"issue":"4","key":"5130_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.21037\/jgo.2018.04.08","volume":"9","author":"AE Chambers","year":"2018","unstructured":"Chambers AE, Frick J, Tanner N, Gerkin R, Kundranda M, Dragovich T (2018) Chemotherapy re-challenge response rate in metastatic colorectal cancer. J Gastrointest Oncol 9(4):679\u2013686. https:\/\/doi.org\/10.21037\/jgo.2018.04.08","journal-title":"J Gastrointest Oncol"},{"key":"5130_CR51","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1200\/PO.20.00109","volume":"4","author":"Y Sunakawa","year":"2020","unstructured":"Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M et al (2020) RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer. JCO Precis Oncol 4:898\u2013911. https:\/\/doi.org\/10.1200\/PO.20.00109","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"5130_CR52","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.5306\/wjco.v15.i9.1232","volume":"15","author":"A Guedes","year":"2024","unstructured":"Guedes A, Silva S, Cust\u00f3dio S, Capela A (2024) Successful cetuximab rechallenge in metastatic colorectal cancer: a case report. World J Clin Oncol 15(9):1232\u20131238. https:\/\/doi.org\/10.5306\/wjco.v15.i9.1232","journal-title":"World J Clin Oncol"},{"key":"5130_CR53","unstructured":"VARUBI\u00ae (rolapitant) \u2013 Official Site for Healthcare Professionals. https:\/\/www.hcp.stivarga-us.com\/. Accessed 15 Nov 2022"},{"issue":"1","key":"5130_CR54","first-page":"e117","volume":"18","author":"T Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab T, Kim R, Kim TW, O\u2019Connor JM, Strickler JH, Malka D et al (2019) Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer 18(1):e117\u2013e129","journal-title":"Clin Colorectal Cancer"},{"issue":"4 suppl","key":"5130_CR55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/jco.2013.31.4_suppl.467","volume":"31","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero AF et al (2013) Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol 31(4 suppl):467","journal-title":"J Clin Oncol"},{"issue":"6","key":"5130_CR56","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629","journal-title":"Lancet Oncol"},{"issue":"9863","key":"5130_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295\u2013302","journal-title":"Lancet"},{"issue":"4","key":"5130_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP et al (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14(4):327\u2013333","journal-title":"Am J Clin Dermatol"},{"key":"5130_CR59","doi-asserted-by":"crossref","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S (2017) Van Cutsem E (2015) Regorafenib-associated hand\u2013foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26(10)","DOI":"10.1093\/annonc\/mdv244"},{"issue":"2","key":"5130_CR60","first-page":"e39","volume":"16","author":"S Fukuoka","year":"2017","unstructured":"Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H et al (2017) Prophylactic Use of oral dexamethasone to alleviate fatigue during regorafenib treatment for patients with metastatic colorectal cancer. Clin Colorectal Cancer 16(2):e39\u2013e44","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"5130_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2017.01.003","volume":"16","author":"JJ Lee","year":"2017","unstructured":"Lee JJ, Chu E (2017) Adherence, dosing, and managing toxicities with trifluridine\/tipiracil (TAS-102). Clin Colorectal Cancer 16(2):85\u201392. https:\/\/doi.org\/10.1016\/j.clcc.2017.01.003","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"5130_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1756283X15580743","volume":"8","author":"SK Krishnamoorthy","year":"2015","unstructured":"Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW (2015) Management of regorafenib-related toxicities: a review. Ther Adv Gastroenterol 8(5):285\u2013297. https:\/\/doi.org\/10.1177\/1756283X15580743","journal-title":"Ther Adv Gastroenterol"},{"key":"5130_CR63","doi-asserted-by":"publisher","first-page":"175883592412993","DOI":"10.1177\/17588359241299324","volume":"17","author":"S Bazarbashi","year":"2025","unstructured":"Bazarbashi S, Abdelsalam A, Al Sharm A et al (2025) Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries. Ther Adv Med Oncol 17:17588359241299324. https:\/\/doi.org\/10.1177\/17588359241299324","journal-title":"Ther Adv Med Oncol"},{"key":"5130_CR64","doi-asserted-by":"crossref","unstructured":"AlSagheir AI, Alrowais NA, Alkhudhair BK, AlYousefi NA, Al Sagheir AI, Ali AM et al (2020) Comparing the use of Arabic decision aid to usual care: a multicenter randomized controlled trial for Arabic speaking metastatic colorectal cancer patients in Saudi Arabia. Saudi Med J 41(5):499\u2013507","DOI":"10.15537\/smj.2020.5.25064"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-026-05130-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-026-05130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-026-05130-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:09:40Z","timestamp":1783987780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-026-05130-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5130"],"URL":"https:\/\/doi.org\/10.1007\/s00384-026-05130-w","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}